About Palatin Technologies, Inc. Common Stock (PTN)
Palatin Technologies is a biopharmaceutical company focused on the development of innovative therapies for a range of medical conditions, including sexual health disorders and other areas with unmet therapeutic needs. The company primarily works on peptide-based drug candidates, leveraging its proprietary technologies to create treatments that target specific physiological pathways. Palatin is committed to advancing its development programs through rigorous research and clinical trials, with the aim of providing effective solutions for patients and improving overall health outcomes. Read More
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.
Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737.
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan drug designation for PL7737, its oral melanocortin-4 receptor (MC4R) agonist, targeting obesity caused by leptin receptor deficiency. According to the company, this designation offers Palatin significant benefits, including tax credits, fee waivers, and potential seven-year market exclusivity upon approval. The company has begun toxicology studies with plans to submit an IND in Q4 2025 and expects clinical data in early 2026.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
